The results of this meta-analysis demonstrate that SGLT2 inhibitors, including dapagliflozin, empagliflozin, canagliflozin, and sotagliflozin, significantly or compellingly reduced CV outcome, including any type of death, HHF, or urgent visit due to HF with no or minimal evidence of heterogeneity among trials. The gene discussed is SLC5A2; the disease is hydrops fetalis.